# Covaxin inches ahead : The World Health Organization’s policy advisory group has completed its review on Bharat Biotech’s Covaxin. The technical review now comes up. Much awaited decision for students and travellers.

Covaxin’s policy review completed, technical review coming up: WHO expert group

# Festivities and vaccinations : The vaccination drive was kept steady on Monday with 60.63 lakh doses administered ahead of the festival season. With the onset of the five-day Durga Puja festival, health experts have sounded a warning against mass gathering, and advised a further push to the vaccination drive.

Durga Puja festivities: Experts warn against mass gathering

# Molnupiravir , different takes in US & India: In less than a fortnight after announcing promising findings on anti-viral drug molnupiravir, Merck and Ridgeback Biotherapeutics have approached the US regulatory authority, seeking emergency approvals for its use in treating Covid. In India, though, two companies have sought to discontinue trials in those with “moderate” illness.

Merck, Ridgeback approach FDA for EUA

# Pandemic opportunity: The Covid pandemic has been an adversity, but the adversity was converted into an opportunity in many sectors, including FMCG, said Venkatesh Vijayaraghavan, Group CEO and Director, FMCG, CavinKare.

‘Covid pandemic converted into opportunity in sectors like FMCG’

# Visually , India outpaces others in daily vaccinations:

India outpaces others in daily vaccination

Related Topics